Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day
BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards…
Investigational Epcoritamab (DuoBody CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response…
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination…
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated…
Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day
BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards…
Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day
BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards…
Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day
BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards…
Microland Foundation and KMF celebrate wellness in the community by distributing dignity kits to patients with disease-related suffering on the occasion of World Disability Day
BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards…
New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average…
A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology
BTL, a leader in medical innovation, is proud to announce a major…